Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Afr. j. urol. (Online) ; 10(1): 1-8, 2004.
Article in English | AIM | ID: biblio-1257940

ABSTRACT

Objectives: To assess any additional benefits of the estimation of serum TGF Beta1 over serum PSA for differentiating localized from metastatic prostatic carcinoma. Patients and Methods: Forty-seven prostate cancer patients (23 with and 24 without metastases) and ten controls were included in the study. Serum PSA was estimated using the chemiluminescent immunometric assay; and serum TGF Beta1 was assessed using the enzyme immunoassay.Results: The mean serum PSA in the localized and metastatic disease groups were significantly higher than that in the control group (p0.001; p0.001 respectively); while the mean serum TGF Beta1 in the metastatic disease group only was significantly higher than in the control: group (p0.01). The mean serum PSA and TGF Beta1 in the metastatic disease group were significantly higher than the values in the localized disease group (p0.001; p0.001 respectively). Serum PSA was directly correlated with Gleason score in both patient groups (localized group: r


Subject(s)
Biological Products , Biomarkers, Tumor , Prostate-Specific Antigen , Prostatic Neoplasms , Transforming Growth Factor beta
SELECTION OF CITATIONS
SEARCH DETAIL